CD38 and Miyoshi myopathy: Breakthrough has also been made in targeting surface molecules expressed by MM cells, such as daratumumab, isatuximab, MOR202 as well as SAR650984 (different generations of humanized anti-CD38 monoclonal antibodies) (78), and elotuzumab, a humanized anti-signaling lymphocytic activation molecule family member 7 mAb.